About Stem Cell Malaysia.
Who We Are
Stem Cell Malaysia was established in 2018 as a one-stop service provider for stem cell therapy in Malaysia. Through a panel of experienced specialists in this field and pharmaceutical research teams specializing in cell culture, we support patients from around the world seeking stem cell therapies.
Our Stem Cells
The stem cells used in our partner clinics are Mesenchymal Stem Cells (MSCs) derived from the Wharton’s Jelly of ethically donated newborn umbilical cords.
Each cell batch is:
- Processed in GMP-certified laboratories audited by the Malaysian Ministry of Health (MOH)
- Undergoes comprehensive safety and sterility testing at every stage of isolation and culture
- Verified for cell viability, potency, and purity before clinical use
This ensures that every patient receives stem cells of exceptional quality, consistency, and safety.
Why Stem Cell Therapy in Malaysia？
Malaysia is a leading nation in the field of healthcare, particularly excelling in stem cell therapy and fertility treatment. In 2011, Malaysia established guidelines for stem cell therapy, and since its practical implementation, the country has accumulated over 13 years of experience in this area. Malaysia’s medical tourism market has seen remarkable growth, driven by numerous initiatives undertaken by the Malaysian government to promote the industry.
One of Malaysia’s most renowned leaders, former Prime Minister Mahathir Mohamad, who is also a medical doctor, played an active role in advancing the country’s healthcare sector. In 2005, the Malaysia Healthcare Travel Council (MHTC) was established, which significantly increased the number of people visiting Malaysia for various treatments. For instance, in 2019, approximately 1.22 million people visited Malaysia for medical purposes.
In 2020, Malaysia gained recognition in the field of “Health & Medical Tourism” and was named “Destination of the Year” at the International Medical Travel Journal (IMTJ) Medical Travel Awards. Recently, the MHTC unveiled the Malaysia Healthcare Travel Blueprint for 2021–2025, aiming to achieve revenue of $380 million USD (1.7 billion MYR) by 2025.
In Switzerland, another leading country in stem cell therapy, receiving a drip treatment using umbilical cord-derived stem cells costs over $70,000 USD. In contrast, in Malaysia, the same treatment is available for approximately $15,000 to $30,000 USD. This highlights a significant advantage of Malaysia: access to high-quality stem cell therapy at a relatively reasonable price.
